New Technologies Help Hospitals Tackle Patient Safety Push
Executive Summary
CMS continues to tighten its rules on so-called "never events" - conditions acquired during hospitalization - in an ongoing effort to slash Medicare costs and improve care for hospitalized patients. And the HAC rules currently in place have already provided significant impetus for hospitals to take steps to improve the identification and prevention of nosocomial infections. Nowa growing group of companies with innovative new technologies aim to capitalize on this trend by helping hospitals take their efforts even further.
You may also be interested in...
Automated Patient Surveillance Systems Take Aim at Hospital Infection Control Practice
Pressure to adopt the latest infection control solutions will continue to grow as payor reimbursement becomes more closely tied to how hospitals perform in the area of health care associated infections. Automated patient surveillance systems offer health care facilities the ability to identify pathogen patterns and identify when control limits have been reached. This may help health care professionals slow or even completely prevent outbreaks, representing a significant improvement over conventional methods of tracking infections.
Diabetes: CGM Goes Mainstream
Getting a breakthrough medical device from the drawing board into mainstream use is the primary goal of every manufacturer, but a variety of factors influences how quickly a device reaches that goal - if at all. Right now, that process is playing out in the diabetes market, where continuous glucose monitoring (CGM) is moving closer to becoming a staple of effective diabetes treatment. The three companies that produce CGM devices - Medtronic, DexCom, and Abbott Laboratories - are very active in demonstrating the value of this technology, but other companies are stepping up in the market. Meanwhile, the focus on CGM is having an effect on other products, including insulin pumps.
Diabetes: CGM Goes Mainstream
Getting a breakthrough medical device from the drawing board into mainstream use is the primary goal of every manufacturer, but a variety of factors influences how quickly a device reaches that goal - if at all. Right now, that process is playing out in the diabetes market, where continuous glucose monitoring (CGM) is moving closer to becoming a staple of effective diabetes treatment. The three companies that produce CGM devices - Medtronic, DexCom, and Abbott Laboratories - are very active in demonstrating the value of this technology, but other companies are stepping up in the market. Meanwhile, the focus on CGM is having an effect on other products, including insulin pumps.